ImmunityBio Inc. stocks have been trading down by -7.2 percent after trial setback news dampened optimism for its cancer pipeline.
Click Here for a Millionaire's POV on Trading IBRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- The FDA issued a Warning Letter on 2026/03/24 saying ImmunityBio’s Anktiva TV ad and podcast were false or misleading, including sweeping “cure all cancer” suggestions and unapproved use claims.
- News of the FDA Warning Letter sparked a more than 21% single-day drop in ImmunityBio’s share price, wiping out roughly $2B in market cap as traders reassessed the Anktiva story.
- Multiple securities-fraud class actions now target ImmunityBio and founder Patrick Soon-Shiong, alleging they overstated Anktiva’s capabilities and misled markets on business prospects and regulatory risks.
- Law firms, including Faruqi & Faruqi, are recruiting shareholders as lead plaintiffs, with a key lead‑plaintiff deadline on 2026/05/26 for those who bought ImmunityBio during the alleged class period.
- Separate from the FDA dispute, updated Phase 2 QUILT 3.078 glioblastoma data was followed by another roughly 12% IBRX share-price decline, underscoring persistent headline risk.
Live Update At 12:32:54 EDT: On Friday, April 24, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -7.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
ImmunityBio Inc. (IBRX) is trading like a classic high‑risk biotech: big dreams, big volatility, and deep red ink. Recent daily data show IBRX bouncing between roughly $6.66 and $8.35 over the past few weeks, with the most recent close near $7.60 after a fade from an $8.28 intraday high. That’s a choppy range, not a steady trend.
Intraday, the 5‑minute chart shows IBRX opening strong around $8.16 but selling off through the morning and grinding down into the mid‑$7.50s by midday. That kind of intraday lower‑high, lower‑low action often signals tired longs and short‑term profit taking. For momentum traders, it screams “trade the volatility, don’t marry the stock.”
More Breaking News
- QXO Stock Grinds Higher As Traders Focus On Turnaround Setup
- American Airlines (AAL) Soars On Mega-Merger Talk Amid Fuel And FAA Risks
- TLRY Stock Slips As Analysts Slash Price Targets
- AUUD Stock Rockets On Patent Win After Reverse Split
Under the hood, ImmunityBio’s fundamentals look heavy. Revenue is only about $113.3M, but the market is valuing the business at roughly $5.27B in enterprise value, implying a steep price‑to‑sales ratio near 73. Gross margin above 99% sounds great, but massive negative profit margins and a deeply negative return on assets show IBRX is still burning cash to chase Anktiva and the rest of its pipeline. The strong current ratio around 5.1 means the company is not about to run out of cash tomorrow, yet the negative book value and large free‑cash‑flow burn remind traders that the balance sheet is built on expectations, not current profits.
Why Traders Are Watching IBRX Now
IBRX is on every active trader’s radar because the story just flipped from “promising oncology platform” to “headline landmine.” The turning point was the FDA Warning Letter made public on 2026/03/24. Regulators said ImmunityBio’s TV ad and a podcast promoting Anktiva were false or misleading. Claims allegedly implied Anktiva could cure or even prevent all cancers, stretched beyond its approved bladder‑cancer indication, and referenced an unapproved subcutaneous route of administration.
When that letter saw daylight, IBRX dropped more than 21% in a single session and roughly $2B in market value evaporated. For traders, that kind of flush is not random — it’s a clear repricing of regulatory and credibility risk. Many funds will treat a fresh FDA Warning Letter as a big red flag, especially when it hits the company’s lead product.
The damage did not stop there. The FDA dispute opened the door to a wave of securities‑fraud class actions against ImmunityBio and Patrick Soon‑Shiong. Complaints claim management materially overstated Anktiva’s capabilities and misled the market about its commercial and clinical profile, as well as about regulatory compliance between 2026/01/19 and 2026/03/24. Several filings highlight that this was not the first FDA communication, pointing to prior “Untitled Letters” and suggesting a pattern.
On top of that, updated Phase 2 QUILT 3.078 glioblastoma data — noting median overall survival had not yet been reached — was followed by another roughly 12% slide in IBRX. Even neutral or incomplete data can become a selling trigger when trust is already strained. Right now, ImmunityBio trades as much on court dockets and FDA letters as it does on charts and trial slides.
Conclusion
For active traders, ImmunityBio Inc. is a live case study in how fast sentiment can turn when a story stock runs head‑first into regulators. An FDA Warning Letter on Anktiva’s TV and podcast promotions, a one‑day 21% drop, roughly $2B in value gone, and a stack of securities‑fraud class actions have pushed IBRX into a high‑headline‑risk category. The allegations center on whether IBRX and its leadership overstated Anktiva’s ability to treat or cure all cancers and glossed over regulatory concerns during the 2026/01/19–2026/03/24 window.
At the same time, the core financials show a company with meaningful cash, high gross margins, but heavy operating losses and a valuation that still bakes in big hopes for Anktiva. That disconnect — rich price‑to‑sales, negative earnings, and mounting legal risk — is exactly what fuels both sharp bounces and brutal dumps in a name like IBRX.
For traders, the playbook is to respect the volatility and the news tape. Lawsuit headlines, any FDA follow‑up, or fresh trial readouts can all move ImmunityBio 10–20% in a day. As Tim Sykes loves to remind his students, “Volatility is opportunity, but only if you cut losses quickly and never believe the hype.” That mindset lines up with a more tactical, day‑to‑day approach to trading names like IBRX; as Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” IBRX is giving the market plenty of volatility; the key is treating it as a trading vehicle, not a belief system, and letting the chart and catalysts, not emotion, dictate your risk.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.